ArticleInternational journal of ophthalmology2026
Efficacy and safety of the VISULAS green with option selective laser trabeculoplasty in pseudoexfoliative syndrome glaucoma and pseudoexfoliative syndrome ocular hypertension.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the effectiveness and safety of VISULAS® green laser selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in patients with pseudoexfoliative syndrome glaucoma (PEXG) and pseudoexfoliative syndrome ocular hypertension (PEXS-OHT).
methodsThis prospective, single-center, interventional study included 20 eyes from 20 patients diagnosed with PEXG or PEXS-OHT. Patients underwent 180° SLT using the VISULAS® green laser, a diode-pumped, frequency-doubled Nd:YVO4 laser with a 532 nm wavelength. IOP was measured at baseline and post-treatment at 1, 3, and 6mo. Medications regimen was stable through the study. Primary outcomes included mean IOP reduction, while secondary outcomes assessed visual and structural parameters, and safety.
resultsThe mean age of participants was 72.2±6.6y, with 65% of the eyes being left eyes and 35% right eyes. At baseline, the mean IOP was 22.9±2.9 mm Hg. A significant reduction in IOP was observed at all follow-up intervals: 18.5±3.1 mm Hg at 1mo (18.8% reduction,
conclusionSLT with the VISULAS® green laser is an effective and safe treatment for PEXG and PEXS-OHT, achieving significant IOP reduction without increasing medication burden or causing severe complications. These findings suggest its potential as an alternative or adjunct therapy in managing pseudoexfoliative glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.